高级搜索

乳腺伴间叶分化的化生性癌28例临床分析

Metaplastic Carcinoma of Breast with Mesenchymal Differentiation: 28 Cases Report

  • 摘要:
    目的  探讨乳腺伴间叶分化的化生性癌的临床病理特征和预后。
    方法  对天津医科大学肿瘤医院2003年至2013年收治的28例乳腺伴间叶分化的化生性癌患者临床及病理资料进行回顾性分析,用Kaplan-Meier法计算生存率并绘制生存曲线。
    结果  全组患者均为女性,发病年龄30~89岁,中位年龄53.5岁;肿瘤平均大小为3.3 cm。雌激素受体(estrogen receptor, ER)、孕激素受体(progesterone receptor, PR)、人表皮生长因子受体(human epithelial growth factor receptor 2, Her-2)阳性率分别为10.7%、10.7%、3%。8例患者发生复发或转移,6例因肿瘤复发转移死亡。28例患者中位随访40月,5年生存率和5年无病生存率分别为64.9%和61%。
    结论  乳腺伴间叶分化的化生性癌发病率低,侵袭性强、受体阳性率低,且治疗后早期容易出现复发或转移,预后差。

     

    Abstract:
    Objective  To investigate the clinicopathological features and the prognosis of metaplastic carcinoma of the breast with mesenchymal differentiation patients.
    Methods  We analyzed retrospectively the clinicopathological data of 28 metaplastic carcinoma of the breast with mesenchymal differentiation patients who were admitted from 2003 to 2013 in Tianjin Medical University Cancer Institute and Hospital. The survival rate was calculated by Kaplan-Meier analysis.
    Results  All patients were females aged 30-89 years(median age 53.5 years). The average maximum diameter of the tumor was 3.3cm. The positive rates of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her-2) were 10.7%, 10.7% and 3% respectively. In the follow-up visits, the recurrence or metastasis were found in eight patients, and six patients died of tumor recurrence and metastasis. The median follow-up was 40 months. Five-year overall survival rate and 5-year disease-free survival rate were 64.9 % and 61%, respectively.
    Conclusion  Metaplastic carcinoma of the breast with mesenchymal differentiation is highly invasive, with low rates of positive receptors and morbidity, early distant metastasis or recurrence after operation, and poor prognosis.

     

/

返回文章
返回